Current situation of Panitumumab, Matuzumab, Nimotuzumab and Zalutumumab

Acta Oncologica

Volumn 47, Issue 1, 2008, Pages 9-19

  Rivera, Fernando ^a   Vega Villegas, Ma Eugenia ^a   Lopez Brea, Marta F ^a   Marquez, Raul ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; GEMCITABINE; HUMAX; IMC 11F8; IRINOTECAN; MATUZUMAB; MONOCLONAL ANTIBODY; N (3,3 DIMETHYL 6 INDOLINYL) 2 (4 PYRIDINYLMETHYLAMINO)NICOTINAMIDE; NIMOTUZUMAB; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; UNCLASSIFIED DRUG; ZALUTUMUMAB;

ACNE; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ASTHENIA; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER THERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COLORECTAL CANCER; CONJUNCTIVITIS; DIARRHEA; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG TOLERABILITY; ESOPHAGUS CANCER; GLIOBLASTOMA; HEAD AND NECK CANCER; HUMAN; HYPOCALCEMIA; HYPOMAGNESEMIA; LUNG NON SMALL CELL CANCER; MONOTHERAPY; NEOPLASM; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SKIN TOXICITY; STOMACH CANCER; THERAPY EFFECT; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CANCER;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; RECEPTOR, EPIDERMAL GROWTH FACTOR; STOMACH NEOPLASMS;

EID: 37549036341     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/02841860701704724     Document Type: Review

References (83)

1. Robinson DR, Wu YM, Lin SF. The protein tyrosine kinase family of the human genome. Oncogene 2000;19:5548-57.
2. Harari PM, Huang SM. Searching for reliable epidermal growth factor receptor response predictors. Clin Cancer Res 2004;10:691-700.
3. Chung CH, Ely K, McGavran L, Varella-Garcia M, Parker J, Parker N, et al. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol 2006;24:4170-6.
4. Dassonville O, Formento JL, Francoual M, Ramaioli A, Santini J, Schneider M, et al. Expresion of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J Clin Oncol 1993;11:1873-78.El 63
5. Hitt R, Ciruelos E, Amador ML, Benito A, Sanchez JJ, Ballestin C, et al. Prognostic value of the epidermal growth factor receptor (EGRF) and p53 in advanced head and neck squamous cell carcinoma patients treated with induction chemotherapy. EurJ Cancer 2005;41:453-60.
6. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. New Engl J Med 2004;351:337-45.
7. Brabender J, Danenberg KD, Metzger R, Schneider PM, Park J, Salonga D, et al. Epidermal growth factor receptor and HER2-NEU mRNA expresion in non-small cell lung cancer is correlated with survival. Clin Cancer Res 2001;7:1850-5.
8. Dragovich T, McCoy S, Fenoglio-Preiser CM, Wang J, Benedetti JK, Baker AF, et al. Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol 2006;24:4922-7.
9. Lordick F, Lorenzen S, Hegewisch-Becker S, Folprecht G, Wöll E, Decker T, et al. Cetuximab plus weekly oxaliplatin/5FU/FA (FUFOX) in 1st line metastatic gastric cancer. Final results from a multicenter phase II study of the AIO upper GI study group. 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25(18S):4526.
10. Burtness B. Her signaling in pancreatic cancer. Expert Opin Biol Ther 2007;7:823-9.
11. Giltnane JM, Rydén L, Cregger M, Bendahl PO, Jirström K, Rimm DL. Quantitative measurement of epidermal growth factor receptor is a negative predictive factor for tamoxifen response in hormone receptor positive premenopausal breast cancer. J Clin Oncol 2007;25:3007-14.
12. Rocha-Lima CM, Soares HP, Raez LE, Singal R. EGFR targeting of solid tumors. Cancer Control 2007;14:295-304.
13. Cohen D, Lane B, Jin T, Magi-Galluzzi C, Finke J, Rini BI, et al. The prognostic significance of epidermal growth factor receptor expression in clear-cell renal cell carcinoma: A call for standardized methods for immunohistochemical evaluation. Clin Genitourin Cancer 2007;5:264-70.
14. Raizer JJ. HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme. J Neurooncol 2005;74:77-86. Review.
15. Pelloski CE, Ballman KV, Furth AF, Zhang L, Lin E, Sulman EP, et al. Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J Clin Oncol 2007;25:2288-94.
16. Edwards J, Traynor P, Munro AF, Pirret CF, Dunne B, Bartlett JM. The role of HER1-HER4 and EGFRvIII in hormone-refractory prostate cancer. Clin Cancer Res 2006;12:123-30.
17. Bellone S, Frera G, Landolfi G, Romani C, Bandiera E, Tognon G, et al. Overexpression of epidermal growth factor type-1 receptor (EGF-R1) in cervical cancer: Implications for Cetuximab-mediated therapy in recurrent/metastatic disease. Gynecol Oncol 2007;106:513-20.
18. Arteaga CL. The epidermal growth factor receptor: From mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol 2001;19:18s,32s-40s.
19. Baselga J. Targeting the epidermal growth factor receptor: A clinical reality. J Clin Oncol 2001;19:18s,41s-44s.
20. Nyati MK, Morgan MA, Feng FV, Lawrence TS. Integration of EGFR inhibitors with radiochemotherapy. Nat Rev Cancer 2006;6:876-85.
21. Ciardiello F, De Vita F, Orditura M, Comunale D, Galizia G. Cetuximab in the treatment of colorectal cancer. Future Oncol 2005;1:173-81.
22. Bernier J. Cetuximab in the treatment of head and neck cancer. Expert Rev Anticancer Ther 2006;6:1539-52.
23. Lilenbaum RC. The evolving role of cetuximab in non-small cell lung cancer. Clin Cancer Res 2006;12(14 Pt 2):4432s-4435s.
24. Frieze DA, McCune JS. Current status of cetuximab for the treatment of patients with solid tumors. Ann Pharmacother 2006;40:241-50. Epub 2006 Jan 10.
25. Nygren P, Sørbye H, Osterlund P, Pfeiffer P. Targeted drugs in metastatic colorectal cancer with special emphasis on guidelines for the use of bevacizumab and cetuximab: An Acta Oncologica expert report. Acta Oncol 2005;44:203-17.
26. Lo K-M, Lan Y, Zhang X. The role of ADCC effector unction in the anti-tumor efficacy of anti-EGFR antibodies in a mouse xenograft model. AACR-NCI-EORTC Int Conf Mol Targets Cancer Ther (Nov 17-21, Boston) 2003, Abstract A123.
27. Yang XD, Jia XC, Corvalan JR, Wang P, Davis CG, Jakobovits A. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res 1999;59:1236-43.
28. Weiner LM, Belldegrun A, Rowinsky E, Crawford J, Lockbaum P, Huang S, et al. Updated results from a dose and schedule study of Panitumumab (ABX-EGF) monotherapy, in patients with advanced solid malignancies. Proc ASCO-05. Abstract 3059.
29. Stephenson J, Cohn A, Crawford J, Maddox A, Lum P, Yang X, et al. Administration of panitumumab (Pmab) as a 30-min or 60-min infusion: Safety and pharmacokinetics (PK) from a phase 1 study in patients (pts) with solid tumors. Proc 2007 Gastrointestinal Cancers Symposium. Abstract 368.
30. Rowinsky EK, Schwartz GH, Gollob JA, Thompson JA, Vogelzang NJ, Figlin R, et al. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Onc 2004;22:3003-15.
31. Heun J, Holen K, Paul P. Treatment with panitumumab after a severe infusion reaction to cetuximab in a patient with metastatic colorectal cancer: A case report. Clin Colorectal Cancer 2007;6:529-31.
32. Langerak AD, Mitchell E, Cheema P, River GL, Shing M, et al. Institutional experiences with panitumumab monotherapy in metastatic colorectal cancer (mCRC) patients (pts) intolerant to cetuximab. 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25(18S):14579.
33. Hecht JR, Patnaik A, Berlin J, Venook A, Malik I, Tchekmedyian S, et al. Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Cancer 2007;110:980-8.
34. Blumenschein G, Jr, Sandler A, O'Rourke T, Eschenberg M, Sun Y, Gladish G, et al. Safety and pharmacokinetics (PK) of AMG 706, panitumumab, and carboplatin/paclitaxel (CP) for the treatment of patients (pts) with advanced non-small cell lung cancer (NSCLC). Proc ASCO 06. Abstract 7119.
35. Peeters M, Van Cutsem E, Berlin J, Hecht JR, Ruiz R, Navale L, et al. Safety of panitumumab, a fully human monoclonal antibody against the epidermal growth factor receptor (EGFr), in patients (pts) with metastatic colorectal cancer (mCRC) across clinical trials. 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25(18S):4138.
36. Heymach JV, Nilsson M, Blumenschein G, Papadimitrakopoulou V, Herbst R. Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer. Clin Cancer Res 2006;12(14 Pt 2):4441s-4445s.
37. Mitchell EP, Hecht JR, Baranda J, Malik I, Richards D, Reiner M, et al. Panitumumab activity in metastatic colorectal cancer (mCRC) patients (pts) with low or negative tumor epidermal growth factor receptor (EGFr) levels: An updated analysis. 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25(18S):4082.
38. Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007;25:1639-41.
39. Van Cutsem E, Siena S, Humblet Y, Canon JL, Maurel J, Bajetta E, et al. An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. Ann Oncol 2007; [Epub ahead of print]
40. Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, et al. A phase III randomized controlled trial of panitumumab (Pmab) in patients (pts) with metastatic colorectal cancer (mCRC): Subset analyses in elderly pts and in pts with poor performance status. 2007 Gastrointestinal Cancers Symposium. Abstract 349.
41. Giusti RM, Shastri KA, Cohen MH, Keegan P, Pazdur R. FDA drug approval summary: Panitumumab (Vectibix). Oncologist 2007;12:577-83.
42. Hecht J, Posey J, Tchekmedyian S, Hu E, Chan D, Malik I, et al. Panitumumab in combination with 5-fluorouracil, leucovorin, and irinotecan (IFL) or FOLFIRI for first-line treatment of metastatic colorectal cancer (mCRC). Proc 2006 Gastrointestinal Cancers Symposium. Abstract 237.
43. Schwartzberg LS, Hurwitz H, Stephenson J, Kotasek D, Goldstein D, Tebbutt N, et al. Safety and pharmacokinetics (PK) of AMG 706 with panitumumab plus FOLFIRI or FOLFOX for the treatment of patients (pts) with metastatic colorectal cancer (mCRC). 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25(18S):4081.
44. Wainberg Z, Hecht JR. Panitumumab in colon cancer: A review and summary of ongoing trials. Expert Opin Biol Ther 2006;6:1229-35.
45. Hecht JR, Chidiac T, Mitchell E, Stella P, Chon A, McCollum D, et al. An interim analysis of efficacy and safety from a randozed controlled trial of Panitumumab with chemotherapy plus Bevacizumab (Bev) for metastatic colorectal cancer (mCRC). Jun. Proc 2007 World Congress on Gastrointestinal Cancer. Ann Oncol 2007;18(Suppl 7):0-0033, vii 21 (Abstract).
46. Harari PM, Allen GW, Bonner JA. Biology of interactions: Antiepidermal growth factor receptor agents. J Clin Oncol 2007;25:4057-65.
47. Lenz HJ, Mayer RJ, Gold PJ, Mirtsching B, Stella PJ, Cohn AL, et al. Activity of cetuximab in patients with colorectal cancer refractory to both irinotecan and oxaliplatin. Proc ASCO, 2004. Abstract 3510.
48. Chung KY, Shia J, Kemeny NE, Shah M, Schwartz GK, Tse A, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by inmunohistochemistry. J Clin Oncol 2005;23:1803-10.
49. Atkins D, Reiffen KA, Tgtmeier CL, Winther H, Bonato MS, Störkel S, et al. Inmunohistochemical detection ofEGFR in paraffin-embedded tumor tissues: Variation in staining intensity due to choice of fixative and storage time of tissue sections. J Histochem Cytochem 2004;52:893-901.
50. Dei Tos AP, Ellis I. Assessing epidermal growth factor receptor expression in tumors: What is the value of current test methods? Eur J Cancer 2005;41:1383-92.
51. Younes M. Is immunohistochemistry for epidermal growth factor receptor expression a poor predictor of response to epidermal growth factor receptor-targeted therapy? J Clin Oncol 2005;23:923. Reply: Saltz L, 923-924.
52. Goldstein NS, Armin M. Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: Implications for a standardized scoring system. Cancer 2001;92:1331-46.
53. Scartozzi M, Bearzi I, Berardi R, Mandolesi A, Fabris G, Cascinu S. Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: Implications for treatment with EGFR-targeted monoclonal antibodies. J Clin Oncol 2004;22:4772-8.
54. Defize LH, Boonstra J, Meisenhelder J, Kruijer W, Tertoolen LG, Tilly BC, et al. Signal transduction by epidermal growth factor occurs through the subclass of high affinity receptors. J Cell Biol 1989;109:2495-507.
55. Bellot F, Moolenaar W, Kris R, Mirakhur B, Verlaan I, Ullrich A, et al. Highaffinity epidermal growth factor binding is specifically reduced by a monoclonal antibody, and appears necessary for early responses. J Cell Biol 1990;110:491-502.
56. Berlin J, Van Cutsem E, Peeters M, Hecht JR, Ruiz R, Wolf, M, et al. Predictive value of skin toxicity severity for response to panitumumab in patients with metastatic colorectal cancer (mCRC): A pooled analysis of five clinical trials. 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25(18S):4134.
57. Moroni M, Veronese S, Benvenuti S, Marrapese G, Sartore-Bianchi A, Di Nicolantonio F, et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: A cohort study. Lancet Oncol 2005;6:279-86.
58. Sartore-Bianchi A, Moroni M, Veronese S, Carnaghi C, Bajetta E, Luppi G, et al. Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J Clin Oncol 2007;25:3238-45.
59. Lièvre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006;66:3992-5.
60. Romagnani E, Martin V, Ghisletta M, Camponovo A, Etienne LL, Caval F, et al. EGFR gene status, K-Ras mutation and PTEN expression predict cetuximab response in metastatic colorectal cancer (mCRC). Proc 2007 Gastrointestinal Cancers Symposium. Abstract 427.
61. Personeni N, De Schutter J, De Hertogh G, Debiec-Rychter M, Geboes K, Van Cutsem E, et al. Response prediction to cetuximab-based therapy: The role of EGFR copy number by fluorescence in situ hybridization and downstream effectors gene mutations. Proc 2007 Gastrointestinal Cancers Symposium. Abstract 400.
62. Finocchiaro G, Cappuzzo F, Jänne PA, Bencardino K, Carnaghi C, Franklin WA, et al. EGFR, HER2 and Kras as predictive factors for cetuximab sensitivity in colorectal cancer. 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25(18S):4021.
63. Khambata-Ford S, Garrett CR, Meropol NJ, Basik M, Harbison CT, Wu S, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007;25:3230-7.
64. De Roock W, De Schutter J, De Hertogh G, Janssens M, Biesmans B, Personeni N, et al. KRAS mutations preclude tumor shrinkage of colorectal cancers treated with cetuximab. 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25(18S):4132.
65. Socinski MA. Antibodies to the epidermal growth factor receptor in non small cell lung cancer: Current status of matuzumab and panitumumab. Clin Cancer Res 2007;13(15 Pt 2):s4597-s4601.
66. Wirth LJ, Posner MR, Tishler RB, Haddad RI, Goguen L, Ckark JR, et al. Phase I study of panitumumab, chemotherapy and intensity-modulated radiotherapy (IMRT) for head and neck cancer (HNC): Early results. 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25(18S):6083.
67. Burger AM, Heiss NS, Kreysch H-G. The humanized monoclonal anti-EGFR antibody EMD72000 potently inhibits the growth of EGFR-expressing human tumor xenografts insensitive to chemotherapeutic drugs. Proc Am Assoc Cancer Res 2003;44:5719 Abstract.
68. Vanhoefer U, Tewes M, Rojo F, Dirsch O, Schleucher N, Rosen O, et al. Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J Clin Oncol 2004;22:175-84.
69. Tabernero J, Rojo F, Jimenez E, Montaner L, Santome M, Guix M, et al. A phase I PK and serial tumor and skin pharmacodynamic (PD) study of weekly (q1w), every 2-week (q2w) or every 3-week (q3w) 1-hour (h) infusion EMD72000, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients (pt) with advanced tumors. Proc ASCO-03. Abstract 770.
70. Blohmer J, Gore M, Kuemmel S, Verheijen R, Kimmig R, Massuger L, et al. Phase II study to determine response rate, pharmacokinetics (PK), pharmacodynamics (PD), safety, and tolerability of treatment with the humanized antiepidermal growth factor receptor (EGFR) monoclonal antibody EMD 72000 (matuzumab) in patients with recurrent cervical cancer. Proc ASCO-05. Abstract 2534.
71. Seiden MV, Burris HA, Matulonis, Hall JB, Armstrong DK, Speyer J, et al. A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies. Gynecol Oncol 2007;104:727-31.
72. Kollmannsberger C, Schittenhelm M, Honecker F, Tillner J, Weber D, Oechsle K, et al. A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC). Ann Oncol 2006;17:1007-13.
73. Graeven U, Kremer B, Südhoff T, et al. Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer. Br J Cancer 2006;94:1293-9.
74. Spicer J. Technology evaluation: Nimotuzumab, the Center of Molecular Immunology/YM BioSciences/Oncoscience. Curr Opin Mol Ther 2005;7:182-91.
75. Crombet T, Torres L, Neninger E, Catala M, Solano ME, Perera A, et al. Pharmacological evaluation of humanized anti-epidermal growth factor receptor, monoclonal antibody h-R3, in patients with advanced epithelial-derived cancer. J Immunother 2003;26:139-48.
76. Brade AM, Magalhaes J, Siu L, Oza A, Lovell S, de Borja M. et al. A single agent, phase I pharmacodynamic study of nimotuzumab (TheraCIM-h-R3) in patients with advanced refractory solid tumors. 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25(18S):14030.
77. Allan DG. Nimotuzumab: Evidence of clinical benefit without rash. Oncologist 2005;10:760-1.
78. Crombet T, Osorio M, Cruz T, Roca C, del Castillo R, Mon R, et al. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol 2004;22:1646-54.
79. Bode U, Buchen S, Warmuth-Metz M, Pietsch T, Bach F, Fleischhack G. Final report of a phase II trial of nimotuzumab in the treatment of refractory and relapsed high-grade gliomas in children and adolescents. 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25(18S):2006.
80. Ramos TC, Figueredo J, Catala M, Gonázlez S, Selva JC, Cruz TM, et al. Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: Report from a phase I/II trial. Cancer Biol Ther 2006;5:375-9.
81. Pendharkar D, Gupta S, Pal MK, Hakim S, Rashid T. Feasibility of combining humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 (nimotuzumab) with chemotherapy-A study of toxicity profile and tolerance. 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25(18S):14151.
82. Dechant M, Lammerts van Bueren J, Peipp M, Bleeker W, Beyer T, Van Berkel P, et al. Impact of antibody Fc carbohydrate fucosylation on antibody-dependent cellular cytotoxicity by HuMax-EGFr -A fully human epidermal growth factor receptor antibody. Proc ASCO-06. Abstract 2543.
83. Bastholt L, Specht L, Jensen K, Brun E, Loft A, Petersen J, et al. A novel fully human monoclonal antibody against Epidermal Growth Factor Receptor (EGFR). First clinical and FDG-PET imaging results from a phase I/II trial conducted by the Danish Head and Neck Cancer Study Group (DAHANCA) in patients with squamous cell carcinoma of the head and neck (SCCHN). Proc ASCO-05. Abstract 5530.